Skip to contentA
Autolus Therapeutics plc
A
AUTLAutolus Therapeutics plc Q1 2024 · 10-Q
Revenue$10.09M$10.09Mno prior Q1 2023 on file Net Income-$52.69M-$52.69MN/M vs Q1 2023 EPS Diluted-$0.24-$0.24N/M vs Q1 2023 Operating Income-$38,757,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
Free Cash Flowderived-$41,047,000N/M Margins · derivedOperating margin-384.1%
Net margin-522.1%
ended Mar 31, 2024 · filed May 17, 2024 · 47 d after period end